Randox & Bosch Healthcare – Collaboratively Combating COVID-19
29th October 2020
Randox & Bosch Healthcare – Collaboratively Combating COVID-19
A game-changing partnership between Randox Laboratories and Bosch Healthcare Solutions continues to change the testing landscape and capabilities of both laboratory and non-laboratory settings in rapidly detecting COVID-19.
Providing clear and concise results, direct at the point of care, the Randox and Bosch Healthcare Solutions collaborative approach not only allows patients to take the recommended safety precautions without delay, but also provides a solution to both analyse and differentiate COVID-19 from other viral respiratory diseases. Multiple testing approaches with the same aim – to overcome COVID-19!
Combining science & technology, timing is of the essence in the fight against coronavirus. Together, we have combined efforts in successfully launching the Vivalytic – the all in one solution for molecular diagnostics consolidating nucleic acid extraction, polymerase chain reaction (PCR) and detection onto one small platform.
These efforts reflect a global partnership of both cooperation’s working together to deliver world-class diagnostic solutions, harnessing the power of innovation to improve health worldwide, providing an all in one approach minimising the spread of COVID-19 globally.
Launched after just six weeks at the beginning of the COVID-19 pandemic back in March 2020, the Viral Respiratory Infection array (VRI) set the benchmark for rapidly detecting SARS-CoV-2 (COVID-19) whilst simultaneously differentiating between nine other respiratory diseases, in under two and a half hours.
Proactively working together to combat the spread of COVID-19, Randox, Bosch Healthcare Solutions and R-Biopharm are proud to offer variable analysis strategies to detect SARS-CoV-2 (COVID-19). Capable of providing reliable results in just 39 minutes, with a sensitivity of 98% and specificity of 100%, the Vivalytic SARS-CoV-2 rapid test is currently among one of the fastest PCR tests worldwide.
Since the outbreak of COVID-19, we have significantly combined our efforts to provide a diverse range of testing solutions and approaches to meet the need of the rise in global cases. Our approaches have been utilised at all possible levels and together we open up a range of different testing strategies, with developments still underway with the upcoming release of the SARS-CoV-2 Pooling test.
The SARS-CoV-2 Pooling test is a rapid solution for the detection of SARS-CoV-2 (COVID-19) offering an accelerated decentral testing approach to effectively and efficiently monitor and detect viral infection from the offset. Capable of detecting SARS-CoV-2 (COVID-19) from up to five pooled samples simultaneously with a capacity to process more than 160 patient samples a day. The pooling could be done at the level of a ward, medical specialty, social bubble, or group of colleagues. It has potential for use in other settings, such as pre-operative screening, schools & universities, prisons, nursing homes, primary care, and large workplaces. Sample pooling allows more people to be tested quickly using fewer testing resources.
Partnering together, we continue to increase our testing capacity, enabling fully automated processing of patient samples to rapidly combat COVID-19.
Please contact marketing@randox.com for further information.
Randox in the media
Latest News
FAQs
Female Bladder Cancer Array
Female Bladder Cancer Array
–
Improved Risk Stratification of Haematuria Patients
Identify Individuals at Greatest Risk of Bladder Cancer
- Improve management of patients with haematuria, reduce unnecessary investigations and refer those at greatest risk of bladder cancer for urgent cystoscopy.
- Simultaneous detection of four novel biomarkers from a single urine sample to determine an individuals biomarker risk score.
- Determine overall bladder cancer risk by combining biomarker risk scores with clinical risk scores generated using our complex algorithms.
There is an urgent critical need for additional evidence-based risk stratification models to inform triage and/or management decisions for patients presenting with haematuria. Current diagnostic methods such as cystoscopy and cytology are invasive, carry risks for the patient and have several limitations.
In addition, existing biomarkers lack specificity and may fail to differentiate between all possible causes of haematuria. Utilising patented biochip technology, the female bladder cancer array will allow accurate risk stratification of female patients presenting with haematuria. Bladder cancer is the 8th most common cancer in females, although more common in males mortality is twice as high in females highlighting the need for alternative diagnostic methods.
Biomarkers Tested
Interleukin-12 p70 (IL12p70) is a disulphide linked heterodimeric cytokine which regulates inflammation by linking innate and adaptive immune responses and potent inducer of antitumor immunity.
Interleukin-13 (IL-13) is an immunoregulatory cytokine which plays an important role in carcinogenesis through affecting tumor immunosurveillance. IL-13 in the bladder cancer patients suggests that this cytokine is involved in progression in bladder cancer patients.
Midkine is a member of a family of heparin-binding growth factors, which was reported to have an important role in angiogenesis and is associated with bladder cancer progression.
Clusterin is conserved glycoprotein that has been distinguished from human fluids and tissues which plays a key role in cellular stress response and survival. It is in cancer metastasis, which is particularly important to design the strategies for treating metastatic patients.
The Evidence Investigator
Meet the Evidence Investigator
Developed for use on the Evidence Investigator, a semi-automated benchtop immunoassay analyser.
- Cost effective and efficient multiplex testing solution
- Comprehensive immunoassay & molecular test menu available
- Limited sample volume requirement
- Medium to high throughput
- Suitable for clinical and research testing
Want to know more?
Contact us or visit our Investigator Webpage
Evidence Investigator: One Analyser for Multiple Food Testing Industries
28 September 2020
The Randox Evidence Investigator: One Analyser for Multiple Food Diagnostic Industries
The Randox Evidence Investigator has been validated for Randox Food Diagnostics across various food matrices including tissue, feed and cereals, honey, aquaculture, and milk, making it the perfect testing equipment solution for any food testing laboratory.
How can the Randox Evidence Investigator benefit me?
- The Randox Evidence Investigator is a multi-analyte quantitative drug residue screening analyser. Using Randox’s patented Biochip Technology, the analyser ensures screening food for drug residues is accurate and efficient, offering a range of laboratories comparable results to LC-MS/MS.
- Using multiplex technology, the Evidence Investigator can provide simultaneous detection for a wide range of analytes from a single sample, saving you time and resource, and getting the reliable results you need.
- The analyser uses unique image processing software to translate the Relative Light Units (RLU) generated from the chemiluminescent reactions into an analyte concentration.
- No manipulation of results is required, which reduces the scope for any operator error. The Randox Evidence Investigator provides excellent sensitivity with a quantitative concentration result (ppb) for each analyte tested.
- The analyser boasts an extensive test menu with tests for the most widely used drug residues and the most commonly detected mycotoxins in the feed production industry.
- When purchasing the Randox Evidence Investigator, you will receive the complete package required for sample analysis which includes the analyser, PC and imaging software, a thermoshaker and a barcode scanner.
Visit the Randox Food Diagnostics website for more information on this technology.
For all enquiries relating to food testing on any of our Randox analysers, please contact us via email at: info@randoxfooddiagnostics.com
Want to know more?
Contact us or visit our Randox Food Diagnostics website.
Related Products
Meat & Seafood
Milk
Honey
Wine
Preparing Your Vineyard for Harvest: A Randox Food Diagnostics Blog
28 August 2020
Preparing your vineyard for harvest: Excellence in every glass
Each year from August through October and maybe a little later, the Northern Hemisphere comes alive with the excitement and rush of harvest as wine makers celebrate with festivals, dinners and get together as the yearlong grape growing season comes to an end and harvest begins.
Producing the highest quality wine grapes is dependent upon many factors – mainly the right amount of sun and rain. The growing process can be stressful for winemakers as they anxiously keep a close eye on weather conditions, in hope that it’s clear of frosts, heatwaves and hail. These can all have detrimental impacts on the vineyard.
However, this year it hasn’t been weather conditions that have been a worry for winemakers. Instead, many vineyards have been significantly impacted by the ongoing COVID-19 pandemic and events that once brought life to local communities and vineyards are now taking place online. Channels for selling wine such as hotels, restaurants and airports have dried up with current restrictions, and online and supermarket sales have never been more important.
Like many industries the food and beverage sector has continued to operate through one of the most challenging times. Using a combination of expert knowledge and technology has ensured that the expectation put upon winemakers to create excellent wine is regularly achieved even in the toughest conditions.
Did you know that a wide range of elements are measured to ensure perfection in every bottle, including levels of acidity and sugar ripeness relevant to the desired style of wine? Technology has been giving winemakers a helping hand in ensuring the quality of each harvest for many years including Randox Food‘s RX misano – a compact, fast and efficient benchtop spectrophotometer capable of gaining results in 8-15 minutes.
For more information please visit Randox Food Diagnostics or email: info@randoxfooddiagnostics.com
Want to know more?
Contact us or visit our Randox Food Diagnostics website.
Related Products
Meat & Seafood
Milk
Honey
Wine
We Are Randox | Staff Newsletter January – July 2020 Edition
Staff Newsletter January - July 2020 Edition
We are delighted to be able to share with you the January – July 2020 edition of our We Are Randox staff newsletter.
Click here to view our news from 2020 so far – including of course our vital work in testing for COVID-19, but also a range of staff announcements including engagements, births and retirements.
** Please note that this newsletter works most efficiently in your Google Chrome browser**
Linearity Verifier Sets
Challenge your Instrument Throughout the Reportable Range with Acusera Linearity Verifier Sets
- Complimentary data reduction software is provided delivering an immediate indication of performance.
- Samples are provided in a user-friendly format with both liquid and lyophilised options available.
- An extended open vial stability keeps waste to a minimum and ensures availability of product for troubleshooting.
- Supplied in a minimum of 5 levels to accurately challenge the AMR and remove the need for manual dilution.
- Ensure specific instrument requirements are met with the availability of dedicated solution for both Roche Cobas and Beckman systems.
- Multi-analyte calibration verifiers will reduce costs, storage space and the number of products required to cover your test menu.
Calibration verification or linearity assessment is defined as the testing of materials of known concentration in the same manner as patient specimens to ensue the test system is accurately measuring samples throughout the reportable range.
CLIA recommend calibration verification once every six months and/or in the event of; a reagent lot change, major preventative maintenance, replacement of critical parts, when QC materials are outside acceptable limits or reflect an unusual trend and as part of new instrument validation.
Our Acusera range of instrument dedicated verifiers are designed to challenge the entire analytical measuring range whilst helping to meet the CLIA requirements. Our range covers Clinical Chemistry, Bilirubin, Apolipoproteins, Enzymes, CRP, Esoterics, Lipids, TDM‘s and more.
Quality Control
EQA
Resource Hub
Contact Us
Ergot Alkaloids ELISA now available from Randox Food Diagnostics
28 July 2020
Ergot Alkaloid ELISA now available from Randox Food Diagnostics
Available now, the Randox Food Diagnostics Ergot Alkaloid ELISA (Catalogue Number EA3491) is:
Compliant with the lowest proposed maximum levels being considered by the European Commission for the total of 12 main ergot alkaloids applicable from July 2020, including the stricter drafted limits from July 2022, for cereal-based feed, wheat and rye milling products.
Accurately detects the sum of 12 main ergot alkaloids to test the most affected type of cereal – rye flour. Randox’s ELISA results show an excellent 95% correlation with the assigned concentration within FAPAS Proficiency Test scheme.
Unrivalled in the detection of low contamination levels. The Z-score of FAPAS PT of -0.6 for baby multigrain food was obtained using Randox Ergot Alkaloids ELISA.
Validated based on Commission Regulation (EC) No 519/2014 as a semi-quantitative screening method for cereal-based feed, wheat and rye milling products. The same regulation was followed for fit-for-purpose approach assessment for confirmatory method, which approves Randox Ergot Alkaloids ELISA as being a method for official control. It is successfully assessed by fit-for-purpose approach according to Commission Regulation (EC) No 401/2006 as approved method of analysis.
Evaluated by third-party laboratory (Wageningen Food Safety research / WFSR, 2019) and proved to be able to distinguish between negative and positive samples. Randox’s ELISA displayed no false-negatives and no false-positives in this study. Across all commercially available ELISA tests, Randox Food Diagnostics Ergot Alkaloids ELISA was the only test which showed good performance with all 3 sample types, including 11 matrices and a total of 24 samples.
Reference reports are available upon request.
For more information visit https://www.randoxfood.com/feed-and-cereals-analysis/ergot-alkaloids/ or email us directly at info@randoxfooddiagnostics.com
Want to know more?
Contact us or visit our Randox Food Diagnostics website.
Related Products
Meat & Seafood
Milk
Honey
Wine
FAQs for Media
Frequently Asked Media Questions
Randox have almost 40 years of experience as a primary manufacturer in the IVD (in vitro diagnostics) industry. Last year we manufactured over 3 billion tests and exported to 145 countries. Randox are an ISO 13485 accredited manufacturer of in-vitro diagnostic medical devices, are a provider of a global laboratory accreditation scheme (RIQAS) accredited to ISO 17043, and run a number of ISO 17025 accredited laboratories. As an exporter to 145 countries and a manufacturer to other diagnostic companies we undergo multiple external audits each year, in order to remain engaged with our global markets.
At the time of the emergence of the COVID-19 threat, Randox had already developed seven CE marked assays for a range of viruses, including a number of other coronaviruses.
Upon identifying the latest strain of coronavirus as a significant global threat, Randox was able to harness our R&D capability, and some 40 years’ in diagnostics, including viral tests, to develop an effective COVID-19 assay with the same rigorous validation processes that we applied to all our other assays.
The Randox COVID-19 test underwent evaluation within, and was accepted by, Public Health England.
In its evaluation of the Randox COVID-19 test, Public Health England’s report noted that the assay correctly identified all positive and negative samples without exception.
As one of the UK’s major life sciences companies, providing diagnostic capabilities both within the UK and globally for almost 40 years, Randox has maintained regular contact with senior officials directly responsible for Life Sciences in the UK, particularly in the fields of diagnostic capability and innovation. We had developed our COVID-19 testing capability by mid-February 2020, and notified officials as such.
Over a number of weeks, we worked collaboratively with government to determine how best we might be able to support the national testing programme.
Our contribution to this programme, which was announced on 27th March, was the culmination of significant engagement, from the identification of the threat, until that date.
The UK Government showed significant confidence in Randox’s capability and conducted full engagement and planning subject to PHE acceptance of the Randox test. When PHE acceptance was granted, the Randox part in the national plan had been prepared and was quickly initiated.
Randox are providing high volume testing within our laboratories.
It should be noted that Randox is only one partner within a multi-partner, national testing programme being run and coordinated by the Department of Health and Social Care.
In order for the testing programme to work efficiently, all partners work to ensure effective processes at each stage of the testing journey – from testing kit distribution and sample collection to transportation and delivery, and finally, the testing of the sample.
For our part, we are focused diligently on processing all tests in a timely manner after receipt of sample at our laboratory.
It is our priority to ensure that we support the national effort to fight COVID-19, by testing at scale, as we know that this is the most effective way to save lives and promote a timely return to a more normal society.
PHE managed the validation process for each of England, Wales, Scotland and Northern Ireland.
We understand that the national plan for COVID-19 testing is exactly that, a national plan, inclusive of Northern Ireland. The planning for the national distribution of test kits is being managed by the various statutory agencies however Randox made the case that tests should be made available locally.
Following that engagement, Randox tests were made directly available within Northern Ireland, and sent, for example, to the drive-through test centre at the SSE arena.
Randox will continue to support Northern Ireland within the UK national plan.
The Randox COVID-19 test is a molecular-based test which looks for SARS-CoV-2 (the virus that causes COVID-19) within the body. PCR (Polyamerase Chain Reaction) techniques are used to detect viral RNA (ribonucleic acid) contained inside the SARS-CoV-2 virus.
The Randox COVID-19 assay conducts two tests – one specific and one confirmatory – as recommended by the World Health Organisation and the Centres for Disease Control and Prevention.
The majority of results are reported within 24 hours of receipt of sample at our laboratories.
The Health Secretary, Matthew Hancock, acknowledged that it was the lack of a significant domestic diagnostic industry that had impeded the Government’s initial efforts on testing, which helps explain the variation between the UK and other countries.
Read an Opinion Piece from our Managing Director, Dr Peter FitzGerald, on the Telegraph Online, by clicking here.
In support of our role within the national testing programme we have invested £85m since March 2020 in the building and equipping of over 80,000 sq ft of molecular laboratory space and the development of new innovations in testing technology in our COVID-19 testing facilities at the Randox Science Park in Northern Ireland.
We have hired more than 850 new staff, and are recruiting for an additional 400 across science, accessioning, customer support and manufacturing.
Find out more here.
On 9th April 2021, Randox processed its 12 millionth sample within the UK COVID-19 National Testing Programme, representing approximately 21% of all PCR tests executed in the UK.
As we continue to ramp up our testing capabilities, and work alongside the government to offer this testing to an increasing list of individuals, we also recognize a demand for testing from the general public – for COVID-safe travel and business.
The Randox COVID-19 test is available to purchase as part of our ‘Get Back to Business’ COVID-19 testing service, for staff screening.
On 13th April 2021 Randox announced its support for British holidaymakers and the travel industry by reducing the cost of its PCR travel test to £60. In order to achieve the £60 price, purchasers will need to apply a discount code which can be obtained from airlines when booking travel. Major airlines including British Airways, Jet2, Easyjet and Ryanair have signed up to provide discount codes for their passengers.⠀
Yes, Randox can conduct antibody testing.
Find out more here.
For COVID-19 press enquiries please email randox@newcenturymedia.co.uk
Want to know more?
Contact us or visit our news page.
Newspage
What We Do
Contact Us
What We Do: Cutting-Edge Healthcare Diagnostics
About Randox
You may already be familiar with Randox! Not only do we sponsor the world’s greatest race, the Randox Grand National, we also have a range of sporting partnerships including Sheffield United Football Club, Olimpia Milano basketball team and more. Or perhaps you recognise the name as being one of the partners in the UK Government’s testing programme for COVID-19.
Disruptive Innovation in Diagnostics and Healthcare
Randox is dedicated to improving healthcare using innovative diagnostic technologies, for a range of health conditions including heart disease, diabetes, Alzheimer’s disease, cancer and stroke.
Whilst the science is complex, the applications are not. Diagnostic testing takes place every day behind the scenes of GP surgeries, laboratories and hospitals.
Around 70% of all medical decisions are based on laboratory results, and so, not surprisingly, we believe that earlier, more accurate and more accessible diagnostics are the key to improving global health and saving lives.
The Future of Healthcare
We are significantly increasing our UK High Street presence, using the unique national coronavirus testing infrastructure and capacity we invested in during the pandemic to deliver a new range of preventative health checks. Expansion plans will see up to 20 new Randox Health clinics operating in the UK and Northern Ireland by the end of the year. The clinics will provide easy access for millions to a range of diagnostic tests for vitamin deficiencies, hormone imbalances, inherited/genetic conditions and key health concerns including heart, liver and kidney conditions.
Key to the unique range of diagnostic testing available at our growing network of clinics is the testing technologies, facilities and comprehensive, nationwide distribution network rapidly developed by Randox Laboratories to play a key role in meeting the sudden national demand for Covid-19 PCR tests. At the height of the pandemic emergency, Randox were the only laboratory in the UK and Northern Ireland to process over 100,000 PCR tests per day, saving thousands of lives.
Now, with millions of people having become accustomed to regular testing through the pandemic, Randox is combining that familiarity with its own unique Covid-19 experience and infrastructure to deliver real, affordable and preventative healthcare through early diagnostic testing on the High Street.
“Randox believes that in harnessing the achievements of during the pandemic we can help the shift away from the traditional model of sickness management to a new era of truly preventative healthcare. This will benefit individuals and society by improving patient outcomes and considerably reducing the burden on our vital and hard-pressed clinical services” (Randox founder and Managing Director – Dr Peter FitzGerald).
Frequently Asked Questions?
What is the vision of Randox?
The Randox ethos of improving healthcare, which drove our Managing Director Dr Peter FitzGerald to start the company in the 1980s, continues today. Up to 25% of our turnover is reinvested in research and development to enable our scientists to work on the development of pioneering tests for a range of common illnesses such as cancer, cardiovascular disease and Alzheimer’s disease.
We have also spent more than £220 million developing our patented Randox Biochip. This state-of-the-art biochip technology has revolutionised the diagnostics industry because it allows multiple tests to be carried out from a single, undivided patient sample on a single testing platform.
When and why was Randox established?
Our Managing Director Dr FitzGerald established Randox in 1982 in County Antrim, Northern Ireland, to address the need for accurate and readily available diagnostic tests to improve patient diagnosis. At that time, doctors only conducted a handful of tests per patient, but now, more than 30 years later, Randox has developed and improved hundreds of tests, with hundreds more in development.
What products and service do Randox offer?
Randox has a broad range of products and services that offer a comprehensive insight into patient diagnosis to facilitate more effective disease management and treatment.
Our clinical product offering includes diagnostic reagents, quality control, and clinical chemistry analysers.
Our patented Randox Biochip Technology and associated Immunoassay analysers also have applications for forensic toxicology, food diagnostics, and workplace drug testing.
Our Randox Health clinics offer a range of health checks across general health, sexual health, respiratory health and more.
Who and where are Randox customers?
Randox’s focus has traditionally been on healthcare providers, so we have placed our products and services in hospitals, clinics, research and molecular laboratories, food testing, forensic toxicology, life sciences and veterinary laboratories.
With the establishment of our consumer brand, Randox Health, we also offer our innovative tests directly to the consumer in our Randox Health clinics, currently located in London, Liverpool, Holywood and Crumlin.
We have ambitious plans to roll out a number of new clinics across the United Kingdom and internationally, over the coming months and years.
What is the size of the company?
Our company has grown from a small team of two scientists, to 1500 employees of 44 nationalities, including 430 research scientists and engineers.
Where are Randox headquartered and what is the geographical reach?
Our headquarters are in Crumlin, in County Antrim, Northern Ireland – close to Belfast International Airport. However, we are a global company and currently have offices and distribution outlets in 145 countries, with manufacturing and R&D capabilities in 4 jurisdictions across 3 continents.
We are currently relocating our headquarters to the Randox Science Park in Antrim; a £161 million project which will accelerate the development of new products into a wide range of clinical needs, including various cancers, stroke, heart disease and neurodegenerative disorders.
We are very proud of our global penetration – today, approximately 5% of the world’s population receives medical diagnoses using products from Randox. That equates to about 370 million people. We also supply 15% of the world’s cholesterol tests, so if you’ve ever had your cholesterol checked, then there’s a high chance it could have been performed using a Randox product!
What are the biggest issues within the health sector?
Our key observation across the globe is that within healthcare the pressure on resources means there is a focus on the “management of sickness,” rather than preventative care.
We know that a focus on early diagnosis and preventative care will improve patient outcomes and reduce the burden on healthcare systems. Making that paradigm shift is a major challenge.
That’s why Randox Health was established – to allow the consumer direct access to our innovative technologies so that they can take control of their health and make appropriate lifestyle changes BEFORE disease manifests and symptoms occur.
What is Randox doing in the fight against COVID-19?
To find out more about our test and testing services for COVID-19, visit our COVID-19 FAQ page by clicking here.
Want to know more?
Contact us or visit our dedication to quality webpage.
Our History
Company Values
Our Accreditations
We Are Randox | Tech Trailblazer Margaret Le Roux
Tech Trailblazers: Margaret Le Roux
Sync NI, in celebration of Women in Tech, recently spoke with our IT Operations Team Leader Margaret.
Read on as Margaret share’s her typical day, the favourite thing about her job, and how her specialist role at Randox combines a degree in Biomedical Science with a passion for software development.
Name: Margaret Le Roux
Role: IT Operations Team Leader, Randox Laboratories
Biography:
I graduated from the University of Rhodesia (now known as Zimbabwe), as a Biomedical Scientist in 1980. My career in South Africa was then predominantly in the clinical laboratory medicine field, and I qualified as a Technical Assessor for clinical laboratories through the South African National Accreditation System. I moved to Belfast in 2014 and started work with Randox.
What does your typical day look like?
I work in an IT Operations role bridging our science and quality control software, which assesses the accuracy and reliability of blood tests, and the machines they are run on, in the likes of hospitals, laboratories, and veterinary clinics. On a typical day, I deal with customer queries about this software, troubleshoot the issues, and drive new developments to improve our systems and applications. I also spend time training Randox staff, mentoring some of my junior colleagues, and speaking at Biomedical Science Conferences to educate others in the industry about the importance of quality control software.
What are you currently working on?
I’m currently working on the specification for our external quality assessment software, which involves a mock blood sample being run in a laboratory’s analyser, and the result being sent back to Randox so that we can independently check that it is performing correctly.
I have also been working on the software project that saw Randox win ‘Project Team of the Year’ at the 2019 Belfast Telegraph IT Awards. This cloud-based quality control technology was specifically designed for ‘Point of Care’ machines which provide finger prick blood tests for conditions like heart disease and diabetes, in pharmacies, GP surgeries and A&E departments.
Did you always want to work in the tech industry?
I have been very lucky that my specialist role at Randox combines my degree in Biomedical Science, and my experience in QC, with my passion for software development. In South Africa, I worked as a Quality Officer for a large private laboratory, with 3 main laboratories and over 100 peripheral sites across 10 African countries. The management of quality control data was a huge job and as such I became interested in a software program that could assist the lab with this task.
What inspired you to join Randox in particular?
Whilst working in South Africa, I was one of Randox’s customers, and made extensive use of their quality control products. Randox has always had a very good reputation in South Africa so when I moved to Belfast it was a natural choice for me.
What’s your favourite part about your work?
It’s a great feeling when we introduce a new release to our software and you know that the customers are going to benefit from it.
What would you say to other people considering a job in the tech industry?
A job in the tech industry is simultaneously exciting and challenging, as each day brings something new. You will continually be making improvements and striving to make something better, which is a good work ethic. It’s really satisfying when you are part of a team which develops a software program that is so well accepted in the market and useful to the customer.
How do you see this technology impacting on our lives?
The technology industry is so fluid and moving at such a fast pace, and there are developments across all industries which are making our lives easier. At Randox in particular, our software is helping a range of healthcare professionals – whether laboratory technicians, clinicians or veterinarians – to achieve our shared goal of saving and improving the lives of patients. It’s rewarding to know we are making a difference.
Who inspired you to work in this field?
In the field of Quality Control, I was inspired by Dr Pandelani Rambau, a Clinical Pathologist from Johannesburg. In IT, it was a colleague Sean Dicks who showed me that there is always a way to get a program to do what you need it to do.
What do you consider to be the most important tech innovation or development in recent years?
The development of communication devices has been incredibly important. They open up the whole world to us and we can access things, both socially and for education, that previously were only available to a few. They have brought so much information to our fingertips.
What tech gadget could you not live without?
I couldn’t live without my phone, because it is so much more than just a phone. It holds all the important things that make up my life, like messages, memories, and my calendar.
To find out more about Randox IT and the vacancies we have in the team, please email recruitment@randox.com
For more We Are Randox stories about our amazing colleagues, make sure to follow us on Facebook, Instagram and Twitter and follow the hashtag #WeAreRandox.
Want to know more?
Contact us or visit our Randox Careers